Actively Recruiting
Phase 3 Study of Intravenous OCTA-C1-INH Versus Placebo for Treating and Preventing Acute Hereditary Angioedema Attacks in Congenital C1-INH Deficiency
Led by Octapharma · Updated on 2026-09-29
124
Participants Needed
25
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of an intravenous human plasma-derived C1 esterase inhibitor C1-INH concentrate in people with congenital C1-INH deficiency who experience acute hereditary angioedema HAE attacks. This phase 3 study compares the C1-INH concentrate to a placebo to treat and prevent acute HAE attacks before procedures. The trial is randomized, double-blind, and involves multiple centers to assess treatment impact on symptom relief. Participants receive either OCTA-C1-INH, a purified human plasma-derived concentrate given as a slow intravenous injection at a dose of 20 IUkg body weight after their first qualifying attack, or a placebo consisting of a sodium chloride injection. The treatment is administered in a blinded manner for some participants, while others receive open-label OCTA-C1-INH. This design aims to measure the treatments ability to relieve symptoms quickly and prevent attacks. During the study, participants are monitored for the time to symptom relief within 4 hours after injection, response rates to treatment, and changes in symptom severity at affected sites. Researchers collect data on the onset of symptom relief and evaluate safety. The study continues until the primary outcome completion date, with participants expected to comply with study procedures and attend scheduled visits for assessment and monitoring.
CONDITIONS
Brief Title
Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks
Research Team
T
Theresa Conklin
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here